Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : NASI (North American Scientific, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: richard houchin who wrote (553)	7/1/1998 10:25:00 PM
From: Solid	Read Replies (1) \| Respond to of 658

Richard, Double D- Thanks for your posts. I too spoke with Al, marketing, at nasi. I called in response to the post from Yahoo thread #174, apparently from a radiation oncologist questioning Mentors aggressiveness with presenting the nasi product. He had found out about nasi from the thrx thread, not the co. reps. Al copied the post and will email mentor and call them to inquire, but was very confident that they were on the right track and gearing up even more, as you noted Richard. Said their production is finding medical consumers as fast as they produce it. He was also very upbeat about the Co. Very pleased with all they had done and were doing. Hiring more personnel, probably moving to larger quarters,(will keep P-103 separate from I-125 area) moving ahead with other irradiation avenues. Said they can use any isotope and molecularly bind it to the structure of any implantable material. Said they assure total privacy and secrecy as different co's., possible competitive to one another, can use nasi as the source of treatment to their implant. Stent is one avenue, but potentially as large as the imagination for uses. I asked about safety. He said the accelerators are in NH and other points, not at their facility. They get the liquid Iodine 125 and seal it into the 'sead pods'. They have numerous air filtration systems, sample air, employee's wear dosimetry patches, get thyroid tests regularly, etc., etc. Very strict. I apologize, I do not remember his last name and the reports do not list it. A very knowledgeable and gracious chap. Genuinely very enthusiastic and positive about the Co. From all I research and speak with, the current price appears to be more and more attractive. Bummer I am down on my entry point, but so it goes. Time should win out in a great way with this Co. Good to see the activity on this thread! Solid

To: richard houchin who wrote (553)	7/2/1998 12:47:00 PM
From: DD™	Read Replies (2) \| Respond to of 658

Radical Prostatectomy Better Than Using Seeds RESEARCH ALERT - Dain cuts brachytherapy cos Reuters, Thursday, July 02, 1998 at 12:36 NEW YORK, July 2 (Reuters) - Dain Rauscher Wessels said Thursday it has lowered its rating on three brachytheraphy or cancer treatment providers. -- Theragenics Corp. (NASDAQ:THRX) cut to neutral from a buy-aggressive. -- Mentor Corp. (NASDAQ:MNTR) cut to neutral from buy. -- North American Scientific Inc. (NASDAQ:NASI) cut to neutral from strong buy. -- Analyst Parice Halbert said supply in sector willovertake demand sooner than expected due to rival Anglo-Norwegian health technology company Nycomed Amersham NYSE:NYE) escalating its capacity expansion sooner than anticipated. -- In addition, an article in June 1998 edition of Urology, comes out in favor of radical prostatectomy over using Iodine seeds on the basis of seven-year disease free rates. -- Halbert lowers Theragenics' fiscal 1999 earnings pershare estimate to $0.67 from $0.77. Also cuts fiscal 2000 EPS to $0.99 from $1.21. Leaves fiscal 1998 EPS unchanged at $0.45. -- Halbert lowers 1999 EPS estimate for North American Scientific to $0.68 from $0.79, and fiscal 2000 cut to $0.89 from $1.16. -- Halbert also lowers Mentor's 1999 and 2000 EPS. -- Halbert said seed prices expected to fall 20 percent in 1999 from current levels, and 30 percent from current levels in 2000 due to growing potential for excess capacity. -- U.S. companies will have to "compete head-to-head sooner than expected to hold or grow market share from Amersham or any new entrants", Halbert said. -- Theragenics off 7-3/16 at 15-1/16. North American Scientific off 3-3/4 at 15-1/4. Mentor sheds 2-3/16 to 21-15/16. Nycomed Amersham up 7/8 at 37. Copyright 1998, Reuters News Service